



PHARMACEUTICAL 2023











PHARMACEUTICAL 2023



Ocuphire Pharma Inc. Rank 3 of 446



The relative strengths and weaknesses of Ocuphire Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ocuphire Pharma Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 168% points. The greatest weakness of Ocuphire Pharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 9.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 377%, being 333% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	48,986
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,753
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	324
Other Liabilities	0
Other Net Income	-14
Other Revenues	39,850
Property and Equipment	6.0
Research and Development	14,355
Selling, General and Administrative Expense	7,269

Output Variable	Value in 1000 USD
Assets	48,992
Liabilities	2,753
Expenses	21,948
Revenues	39,850
Stockholders Equity	46,239
Net Income	17,888
Comprehensive Net Income	17,888
Economic Capital Ratio	377%

